Portfolio

Atrosimab is a novel monovalent, TNFR1-selective antibody designed to selectively block pro-inflammatory TNFR1 signaling while preserving the beneficial immune-regulatory and tissue-protective functions of TNFR2. Due to its unique monovalent architecture, Atrosimab avoids unwanted TNFR1 crosslinking and receptor activation, providing a differentiated mechanism for improved safety.

Atrosimab has demonstrated therapeutic activity in multiple preclinical models of acute and chronic inflammation and offers broad potential across inflammatory, immunological, and tissue-injury diseases. A FIH Phase I trial has been successfully conducted, confirming the safety and tolerability of Atrosimab.

Lead indication: Immunological & Inflammatory diseases

VAL111 | Platuzumab

Our novel immune checkpoint inhibitor program targets the platelet-tumor immune-evasion axis to restore anti-tumoral immunity. By neutralizing TLT-1 released by activated platelets, the program is designed to relieve suppression of cytotoxic immune cells and reverse key mechanisms of immune exclusion.

This differentiated approach has the potential to complement conventional immune checkpoint blockade by addressing a novel platelet-driven layer of tumor immune suppression.

Lead indication: Solid tumors and metastasizing tumors

VAL211 | Velistamab

Our novel bispecific immunotherapy combines a platelet-targeted immune checkpoint inhibitor with RANKL blockade to simultaneously address two complementary mechanisms of tumor immune evasion. By neutralizing platelet-derived immunosuppressive signals while disrupting the RANKL/RANK axis, the program is designed to restore anti-tumor immunity, enhance immune-cell activity, and remodel the tumor microenvironment.

The dual-targeting approach offers a differentiated strategy to address immune suppression, tumor progression, and metastatic disease within a single therapeutic molecule.

Lead indication: Solid tumors and metastasizing tumors